Regeneron Pharmaceuticals, Inc. (REGN)
Company Info
Highlights
$65.57B
$38.33
15.65
0.96
$11.06B
$9.40B
$3.94B
$525.99 - $1,209.65
$852.30
2.69%
2.80
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Regeneron Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Regeneron Pharmaceuticals, Inc. had a return of -15.29% year-to-date (YTD) and -32.25% in the last 12 months. Over the past 10 years, Regeneron Pharmaceuticals, Inc. had an annualized return of 2.62%, while the S&P 500 had an annualized return of 10.11%, indicating that Regeneron Pharmaceuticals, Inc. did not perform as well as the benchmark.
REGN
-15.29%
-5.86%
-35.33%
-32.25%
1.28%
2.62%
^GSPC (Benchmark)
-6.06%
-3.27%
-4.87%
9.44%
14.30%
10.11%
Monthly Returns
The table below presents the monthly returns of REGN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -5.52% | 3.96% | -9.23% | -4.98% | -15.29% | ||||||||
| 2024 | 7.34% | 2.47% | -0.37% | -7.46% | 10.05% | 7.23% | 2.68% | 9.78% | -11.26% | -20.27% | -10.50% | -5.05% | -18.90% |
| 2023 | 5.13% | 0.26% | 8.05% | -2.42% | -8.26% | -2.31% | 3.25% | 11.40% | -0.43% | -5.23% | 5.63% | 6.61% | 21.73% |
| 2022 | -3.63% | 1.61% | 12.95% | -5.63% | 0.85% | -11.07% | -1.60% | -0.11% | 18.55% | 8.69% | 0.39% | -4.02% | 14.25% |
| 2021 | 4.29% | -10.57% | 5.01% | 1.72% | 4.39% | 11.17% | 2.88% | 17.19% | -10.13% | 5.74% | -0.53% | -0.79% | 30.72% |
| 2020 | -10.00% | 31.55% | 9.83% | 7.70% | 16.53% | 1.77% | 1.35% | -1.92% | -9.70% | -2.90% | -5.06% | -6.38% | 28.66% |
| 2019 | 14.93% | 0.34% | -4.67% | -16.43% | -12.07% | 3.74% | -2.63% | -4.83% | -4.36% | 10.41% | 20.48% | 1.76% | 0.53% |
| 2018 | -2.48% | -12.60% | 7.46% | -11.81% | -1.11% | 14.87% | 6.67% | 10.53% | -0.67% | -16.04% | 7.79% | 2.15% | -0.65% |
| 2017 | -2.12% | 3.96% | 3.75% | 0.25% | 18.17% | 6.99% | 0.10% | 1.07% | -10.02% | -9.95% | -10.12% | 3.90% | 2.42% |
| 2016 | -22.62% | -8.59% | -6.14% | 4.51% | 5.90% | -12.46% | 21.73% | -7.66% | 2.41% | -14.18% | 9.92% | -3.20% | -32.38% |
| 2015 | 1.56% | -0.68% | 9.10% | 1.32% | 12.04% | -0.47% | 8.53% | -7.25% | -9.42% | 19.83% | -2.31% | -0.30% | 32.33% |
| 2014 | 4.85% | 15.22% | -9.69% | -1.13% | 3.39% | -7.98% | 11.95% | 10.83% | 2.87% | 9.21% | 5.69% | -1.41% | 49.05% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of REGN is 10, meaning it’s performing worse than 90% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Regeneron Pharmaceuticals, Inc. provided a 0.15% dividend yield over the last twelve months, with an annual payout of $0.88 per share.
| Period | TTM |
|---|---|
| Dividend | $0.88 |
Dividend yield | 0.15% |
Monthly Dividends
The table displays the monthly dividend distributions for Regeneron Pharmaceuticals, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.88 | $0.00 | $0.00 | $0.88 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Regeneron Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Regeneron Pharmaceuticals, Inc. was 91.81%, occurring on Apr 14, 2005. Recovery took 1520 trading sessions.
The current Regeneron Pharmaceuticals, Inc. drawdown is 49.79%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -91.81% | Mar 1, 2000 | 1287 | Apr 14, 2005 | 1520 | Apr 27, 2011 | 2807 |
| -86.67% | Feb 7, 1992 | 733 | Dec 30, 1994 | 446 | Oct 4, 1996 | 1179 |
| -77.41% | Oct 9, 1996 | 628 | Apr 7, 1999 | 223 | Feb 23, 2000 | 851 |
| -54.48% | Aug 28, 2024 | 155 | Apr 10, 2025 | — | — | — |
| -53.84% | Aug 6, 2015 | 1044 | Sep 27, 2019 | 168 | May 29, 2020 | 1212 |
Volatility
Volatility Chart
The current Regeneron Pharmaceuticals, Inc. volatility is 12.57%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an overview of how Regeneron Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
PEG Ratio
PS Ratio
PB Ratio
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |